story of the week
Safety and Efficacy of Intravenous Recombinant Human Prourokinase for Acute Ischaemic Stroke Within 4.5 Hours After Stroke Onset
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4·5 h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial
Lancet Neurol 2024 Nov 28;[EPub Ahead of Print], S Li, HQ Gu, B Feng, H Li, X Wang, Q Dong, D Fan, Y Xu, S Zhu, H Dai, Y Wei, Z Wang, G Lu, Y Ma, Z Li, Y Wang, X Meng, X Zhao, L Liu, Y WangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.